Trial Profile
A Phase II Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary) ; Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 18 Sep 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Jan 2024.
- 19 Sep 2022 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.
- 19 Sep 2022 Planned primary completion date changed from 1 Aug 2022 to 1 Aug 2023.